Crystallization (Comment) | Organism |
---|---|
in complex with inhibitor 3-[[4-(trifluoromethyl)phenyl]amino]benzoic acid. Compound adopts a similar binding orientation as flufenamic acid, however, its phenylamino ring projects deeper into a subpocket and confers selectivity over the other AKR1C isoforms | Homo sapiens |
Inhibitors | Comment | Organism | Structure |
---|---|---|---|
3-((4-nitronaphthalen-1-yl)amino)benzoic acid | inhibitor nanomolar potency and selective inhibition of isoform AKR1C3 but also acts as an androgen receptor antagonist. It inhibits 5alpha-dihydrotestosterone stimulated androgen receptor reporter gene activity with an IC50 value of 4.7 microM and produces a concentration dependent reduction in androgen receptor levels in prostate cancer cells | Homo sapiens | |
3-[[4-(trifluoromethyl)phenyl]amino]benzoic acid | in complex with AKR1C3. Compound adopts a similar binding orientation as flufenamic acid, however, its phenylamino ring projects deeper into a subpocket and confers selectivity over the other AKR1C isoforms | Homo sapiens |
Organism | UniProt | Comment | Textmining |
---|---|---|---|
Homo sapiens | P42330 | - |
- |
Synonyms | Comment | Organism |
---|---|---|
AKR1C3 | - |
Homo sapiens |
IC50 Value | IC50 Value Maximum | Comment | Organism | Inhibitor | Structure |
---|---|---|---|---|---|
0.08 | - |
pH not specified in the publication, temperature not specified in the publication | Homo sapiens | 3-((4-nitronaphthalen-1-yl)amino)benzoic acid |